MedPath

Feasibility and Impact of an Intensive Team-based Intervention on Type 2 Diabetes Reversal

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Behavioral: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting
Registration Number
NCT05495451
Lead Sponsor
Montreal Heart Institute
Brief Summary

To evaluate the feasibility of a 6-month multidisciplinary program to reverse type 2 diabetes using the Mediterranean diet, intermittent fasting and exercise.

Detailed Description

The morbidities associated with type 2 diabetes (Db2) are major, including cardiovascular and renal complications, but also cognitive impairment. Providing interventions targeting Db2 reversal has shown great potential to improve healthy aging.

A Db2 reversal clinic has been established at the Montreal Heart Institute's ÉPIC Center, with an approach based on the Mediterranean diet and exercise. First-year results showed a 0.6% decrease in Hb1Ac and an average weight loss at 3 months of 4.5 kg in diabetic patients. This improvement was maintained at 6 and 12 months. Although these results are encouraging, the literature in Db2 remission shows that a weight loss of 10 kg is the ideal goal.

Therefore, to offer the possibility of further metabolic improvement at 6 months, three interventions are proposed as additions to the current program: targeting ultra-processed food reduction, motivational coaching and intermittent fasting. The main objective of our pilot study is to determine the feasibility of this improved program in type 2 diabetic patients, aged 18 to 80 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Type 2 diabetes
  • Ability to give written consent, to use a smartphone application or complete an adherence/compliance diary, and use a blood glucose and blood pressure machine at home.
Exclusion Criteria
  • All types of diabetes other than type 2
  • Taking the following glucose-lowering agents: insulin, sulfonylureas
  • BMI < 18,5 kg/m2
  • Unintentional weight loss of more than 10 kg in the past year
  • Moderate to severe retinopathy
  • Pregnant or nursing woman
  • Severe organ failure
  • Pathologies predisposing to gastrointestinal bleeding, untreated
  • Recent cholecystitis (3 months)
  • Antibiotic use in the past 3 months, or untreated active infection
  • Known impaired nutrient absorption
  • Uninvestigated new anemia or Hb < 110 g/100 mL
  • Currently following an intermittent or prolonged fasting protocol
  • Currently following a specific diet (vegan, celiac/gluten free, ketogenic)
  • Active diagnoses of psychiatric or neurological illness not controlled for at least 6 months
  • Taking, stopping or adjusting a medication in the last 3 months resulting in an active weight change.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mediterranean diet and Personalized trainingModerate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting36 participants will participate to the following lifestyle changes for 6 months: Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet. Personalized exercise prescription and training (3 times per week) Personalized education and motivational interviewing
Intermittent Fasting InterventionModerate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fastingBetween 3 and 6 months, 24 participants (on a total of 36) will progressively integrate intermittent fasting 16:8 (5 times/week for 12 weeks) and 20:4 (2 times/week for 4 weeks)
Primary Outcome Measures
NameTimeMethod
Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.at 6 months after the start of the intervention

Total recruitment, recruitment rate, compliance and completion rate at 6 months after the start of the intervention

Secondary Outcome Measures
NameTimeMethod
Proportion of diabetic participants in complete remission of diabetes.at 3 and 6 months of the start of the intervention

Remission of diabetes will be defined by the following 3 criteria:

1. An HbA1c \< 6,5% at 3 months of intervention (Metabolic criteria)

2. Which is maintained at 6 months (Duration criteria)

3. Without the use of glucose-lowering agents (Pharmacological criteria)

Proportion of prediabetic patients that reach an Hb1Ac \< 6,5% at 6 months of intervention will also be studied

Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).at 3 and 6 months of the start of the intervention

HOMA-IR is a marker of insulin resistance

Trial Locations

Locations (1)

EPIC Center of the Montreal Heart Institute

🇨🇦

Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath